Net sales grew 7.5% Y/Y to $5.44B, with adjusted EPS up to $0.86 and gross margin at 70.7%. Cardiovascular and neuromodulation segments led growth, while a $2B share repurchase and $1.5B MiRus investment marked significant capital moves.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.